Tremfya Market Report Scope & Overview:

The Tremfya Market was valued at USD 3.88 Billion in 2025 and is expected to reach USD 8.36 Billion by 2035, growing at a CAGR of 7.98% from 2026 to 2035.

The market expansion of Tremfya is a result of the availability of guselkumab in the IL-23 inhibitors category, which is initially approved by the FDA to treat patients suffering from moderate to severe plaque psoriasis and psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Recent advancements in the market have seen Tremfya acquire additional approval for ulcerative colitis from the FDA in 2024 and Crohn's disease in 2025, thereby providing the company with an entirely new customer base outside the dermatological disease field. Clinical results obtained from the Phase 3 clinical trial APEX in the treatment of psoriatic arthritis further have helped Tremfya strengthen its position in the biologics market.

Johnson & Johnson announced new data from the Phase 3b APEX study in a newsroom release on June 11, 2025, showing that guselkumab is the only IL-23 inhibitor proven to significantly inhibit progression of joint damage in patients with active psoriatic arthritis, reinforcing Tremfya's positioning as a first-in-class therapy capable of addressing both symptomatic relief and long-term structural joint protection.

Market Size and Forecast

• Market Size in 2026E: USD 4.19 Billion
• Market Size by 2035: USD 8.36 Billion
• CAGR: 7.98% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information On Tremfya Market - Request Free Sample Report

Tremfya Market Trends

• Expanding therapeutic indications into inflammatory bowel disease continue opening entirely new patient populations for the drug.
• Clinical data demonstrating structural joint damage inhibition continues differentiating Tremfya within a crowded IL-23 inhibitor class.
• Johnson & Johnson is actively building a pipeline of next-generation oral IL-23 receptor antagonist therapies targeting similar pathways.
• Structured patient assistance programs continue improving access for uninsured and underinsured populations facing high biologic treatment costs.
• Rising dermatologist and gastroenterologist awareness of guselkumab's efficacy and safety profile continues supporting broader clinical adoption.

The United States Tremfya Market Outlook

The United States Tremfya Market was valued at USD 3.26 Billion in 2025 and is expected to reach USD 5.52 Billion by 2035, growing at a CAGR of 5.41% from 2026 to 2035.

The US had a strong position within the global Tremfya market owing to the increasing prevalence of chronic plaque psoriasis and psoriatic arthritis in addition to a well-diagnosed and insured patient pool. Due to the large number of patients along with the effectiveness of Tremfya, it remained one of the first options chosen by dermatologists and their patients. Since these diseases are chronic in nature, this created sustained demand and ensured that the US remained the largest market for this drug therapy.

Tremfya by Johnson & Johnson was granted FDA approval for the condition in March 2025 as the first-ever IL-23 inhibitor to feature both subcutaneous and intravenous induction options for moderately to severely active Crohn's disease in adults. This marked an extension of Tremfya's usage from psoriasis and arthritis to inflammatory bowel disease.

Tremfya Market Segment Analysis

• By Indication, the Plaque Psoriasis segment held approximately 87.30% share in 2025, while the Inflammatory Bowel Disease segment is the fastest growing.
• By Route of Administration, the Subcutaneous segment held the largest share in 2025, while the Intravenous segment is the fastest growing.
• By Distribution Channel, the Specialty Pharmacies segment held the largest share in 2025, while the Hospital Pharmacies segment is the fastest growing.
• By End User, the Dermatology Clinics segment held the largest share in 2025, while the Gastroenterology Clinics segment is the fastest growing.

By Indication, plaque psoriasis led the market, inflammatory bowel disease grew fastest

Plaque psoriasis accounted for the highest share in the indication market segment during the year 2025, accounting for about 87.30% of the total revenue generated from the segment owing to the high prevalence of severe cases and increasing need for targeted biologics. Guselkumab, an IL-23 inhibitor, has proven to be highly effective in skin clearance and prolonged disease management in several clinical studies; increased awareness among dermatologists has further enhanced its popularity for treating plaque psoriasis.

The inflammatory bowel disease segment, encompassing the newer ulcerative colitis and Crohn's disease indications, is projected to grow at the fastest CAGR during the forecast period. The recent regulatory approvals for these conditions are opening up entirely new patient populations for the drug, and Tremfya's demonstrated superiority versus ustekinumab in Crohn's disease treatment continues reinforcing its potential as a key therapy in inflammatory bowel disease management, pushing this indication category's growth rate well ahead of the broader indication segmentation.

By Route of Administration, subcutaneous led the market, intravenous grew fastest

The subcutaneous segment held the largest route of administration share in 2025, remaining the established, patient-preferred dosing method across the drug's original psoriasis and psoriatic arthritis indications. That established treatment pathway, combined with the convenience of at-home or in-office subcutaneous injection, continues keeping this route of administration firmly at the top of the broader segmentation.

The intravenous segment is projected to grow at the fastest CAGR during the forecast period, as Tremfya's newly approved intravenous induction option for Crohn's disease offers flexible treatment methods that improve patient outcomes for patients requiring more intensive initial dosing. That expanded dosing flexibility continues pushing intravenous administration adoption ahead of the broader route of administration segmentation as the inflammatory bowel disease patient population continues to grow.

By Distribution Channel, specialty pharmacies led the market, hospital pharmacies grew fastest

The specialty pharmacies segment held the largest distribution channel share in 2025, reflecting the established biologic drug distribution infrastructure that manages complex reimbursement, cold-chain storage, and patient support services for high-cost injectable therapies. That specialized distribution capability continues keeping specialty pharmacies the dominant channel across the majority of Tremfya prescriptions filled for dermatology and rheumatology patients.

The hospital pharmacies segment is projected to grow at the fastest CAGR during the forecast period, as the newly approved intravenous induction option for Crohn's disease requires infusion center or hospital-based administration that community specialty pharmacies typically cannot provide. That shift toward hospital-based administration for inflammatory bowel disease patients continues pushing this distribution channel's growth rate ahead of the broader distribution channel segmentation.

By End User, dermatology clinics led the market, gastroenterology clinics grew fastest

The dermatology clinics segment held the largest end-user share in 2025, anchored by Tremfya's origins as a plaque psoriasis therapy and the drug's deep integration into established dermatology treatment protocols. That established clinical relationship keeps dermatology clinics firmly at the center of overall Tremfya prescribing volume across nearly every major regional market.

The gastroenterology clinics segment is projected to grow at the fastest CAGR during the forecast period, as the drug's expanded indications for ulcerative colitis and Crohn's disease continue building new prescribing relationships within the gastroenterology specialty. Rising gastroenterologist familiarity with guselkumab's clinical data continues pushing this end-user category's growth rate ahead of the broader end-user segmentation.

Regional Analysis

North America Tremfya Market Insights

North America held the largest share of the global Tremfya market in 2025, at over 85.00%, driven by early regulatory approvals, high diagnosis rates, and broad insurance coverage across the region. The presence of a large number of patients, early use of biologics, and R&D activities of Johnson & Johnson in the US strengthened the region’s leadership role through the year under review.

The US comprised about 84.00% of regional revenues owing to the prevalence of centers of dermatology and rheumatology treatments along with favorable reimbursement environment. Contribution of Canada to regional revenues was lower but gradually increasing on account of the increasing adoption of biologic therapies in the region, and thus North America remained ahead of all regions in this market.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Tremfya Market Insights

Europe held a substantial share of the global Tremfya market in 2025, supported by the drug's European approval for Crohn's disease in 2025 and well-established national health insurance coverage for biologic therapies across the continent. The market share of Germany was approximately 27.80%, owing to the country’s strength in dermatology and gastroenterology treatment centers and full-fledged healthcare system. The pattern was also followed by France, the United Kingdom, and Italy due to increased use of Tremfya in the largest European markets due to European approvals. Continued reimbursement support for biologic therapies is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific Tremfya Market Insights

Asia Pacific was the fastest-growing region in the global Tremfya market, driven by rising chronic inflammatory disease prevalence, expanding healthcare infrastructure investment, and growing biologic therapy adoption across the region's largest economies. Rising dermatologist and gastroenterologist awareness of guselkumab's clinical benefits continued driving regional demand at a pace considerably faster than more mature Western markets.

The Japanese market accounted for around 35.60% of the regional revenue because of the availability of well-developed health care infrastructure along with the usage pattern of biologic therapies. The demand from China and South Korea added to the growth of the regional revenue because of their growing access to biologic therapies programs.

MEA & Latin America Tremfya Market Insights

The Middle East and Africa region recorded steady growth in Tremfya adoption in 2025, driven by expanding specialty healthcare infrastructure investment and growing biologic therapy access across the Gulf states in particular. UAE was contributing about 26.10% of revenue from the region due to national healthcare reform initiatives and increasing demand for innovative solutions in dermatology and gastroenterology treatments.

Latin America witnessed growth at similar rates with Brazil contributing about 37.40% of revenue from the region owing to increased availability of specialty pharmaceutical products. Mexico and Argentina followed a similar trajectory as regional biologic therapy adoption expanded further through the remainder of the forecast period.

Growth Drivers: Indication expansion and structural joint damage clinical differentiation

The increasing number of people affected by chronic plaque psoriasis and psoriatic arthritis continues to be the central force behind Tremfya market growth, boosting demand for advanced biologic treatments capable of delivering superior, long-term disease control. Recent FDA approvals for ulcerative colitis and Crohn's disease have significantly broadened the drug's market potential, opening entirely new patient populations well beyond the drug's original dermatology indications.

Clinical data demonstrating that guselkumab significantly inhibits progression of joint structural damage in psoriatic arthritis continues reinforcing Tremfya's competitive edge in an increasingly crowded biologics market. Ongoing and significant investment in research and development by Johnson & Johnson, including a pipeline of next-generation oral IL-23 receptor antagonist therapies, continues reinforcing structural demand growth across nearly every major indication category.

Restraints: High treatment cost and biosimilar competitive pressure

The expensive nature of biologics such as Tremfya has continued to limit access among the uninsured and underinsured population, who frequently experience financial difficulties, which may affect their access to the treatment or result in use of alternative less efficient means of treatment. The issue of affordability has remained a key factor needing patient assistance programs.

Competition from established IL-23, IL-17, and TNF inhibitor biologics offered by AbbVie, Eli Lilly, Novartis, Amgen, and UCB continues creating genuine competitive pressure within an increasingly crowded biologics market. That competitive intensity continues requiring sustained clinical differentiation and real-world outcomes data to maintain and expand Tremfya's market position against alternative treatment mechanisms.

Opportunities: Oral IL-23 antagonist pipeline and pediatric indication expansion

JNJ-2113 by Johnson & Johnson, which is a novel oral IL-23 receptor antagonist that has yielded encouraging outcomes from its Phase 2b clinical trial studies on psoriasis, creates a significant possibility of working alongside Tremfya by providing an oral alternative. That pipeline diversification stands to capture a growing share of demand from patients hesitant about biologic injection therapy.

Continued pursuit of additional approvals, particularly for pediatric inflammatory bowel disease, presents a further significant growth avenue, as structured patient assistance programs could lead to earlier intervention and improved disease management in underserved populations. Johnson & Johnson stands to capture meaningful new revenue streams as label expansion into additional patient populations continues through 2035.

Recent Developments:

• 2026: The U.S. FDA approved a label expansion for TREMFYA® (guselkumab) to include evidence that it inhibits the progression of structural joint damage in adults with active psoriatic arthritis, making it the first and only IL-23 inhibitor with this claim.
• 2024: Johnson & Johnson announced FDA approval of Tremfya for adults with moderately to severely active ulcerative colitis in September, expanding the drug's use into inflammatory bowel disease for the first time.
• 2024: Johnson & Johnson announced in May that Tremfya's Phase 3 study showed superior results versus ustekinumab in treating Crohn's disease, highlighting the drug's strong efficacy for moderate to severe cases ahead of its subsequent regulatory approval.

Tremfya Market key players are:

• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• UCB S.A.
• Amgen Inc.
• Bristol Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Biocon Biologics Limited
• MorphoSys AG
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Genentech, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Celltrion, Inc.
• Samsung Bioepis Co., Ltd.

Tremfya Market Report Scope :